Blog

拥抱模型引导的药物发现：通往更佳临床疗效之路

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026 年 2 月 27 日

博客

Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026 年 2 月 26 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

On-Demand Webinar

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…

Certara2026 年 2 月 23 日

Blog

FAQs: The ICH M15 guideline and what it means for model-informed drug development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026 年 2 月 18 日

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

Certara2026 年 2 月 13 日

Blog

Pediatric drug development: From “wild west” to model-informed confidence

Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…

Certara2026 年 2 月 11 日

Blog

QSP in inflammatory bowel disease (IBD): From biomarkers to clinical endpoints, with virtual patients

Certara supports IBD drug development with a QSP model that predicts Mayo score and CDAI…

Certara2026 年 2 月 10 日

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

Certara2026 年 2 月 2 日

Conference

Quantitative Systems Pharmacology Conference

Certara2026 年 1 月 26 日

建模与模拟

拥抱模型引导的药物发现：通往更佳临床疗效之路

Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

FAQs: The ICH M15 guideline and what it means for model-informed drug development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Pediatric drug development: From “wild west” to model-informed confidence

QSP in inflammatory bowel disease (IBD): From biomarkers to clinical endpoints, with virtual patients

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Quantitative Systems Pharmacology Conference

订阅时事通讯

快捷链接

解决方案

联系我们